Read-Gene Company Description

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer.

Its activities include chemoprevention, clinical tests, and genetic tests. Chemoprevention is the use of natural or synthetic substances to stop, reverse, or delay the process of developing cancer.

The company conducts clinical trials in cancer patients; and provides genetic tests and genetic-oncological consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer.

Read-Gene S.A. was incorporated in 2005 and is based in Dobra, Poland. Read-Gene S.A. is a subsidiary of Gen-Pat-Med Sp.

z o.o.

Read-Gene S.A.

Country	Poland
Founded	2005
Industry	Biotechnology & Medical Research
Sector	Healthcare
Employees	29
CEO	Jan Lubinski

Contact Details

Address: ul. Alabastrowa 8 Dobra, 72-003 Poland
Phone	48 91 433 4256
Website	read-gene.com

Stock Details

Ticker Symbol	RDG
Exchange	Warsaw Stock Exchange
Fiscal Year	January - December
Reporting Currency	PLN
ISIN Number	PLRADGN00014
SIC Code	2836

Key Executives

Name	Position
Jan Lubinski	Chief Executive Officer
Karolina Ertmanska	Chief Financial Officer